Mithramycin A and Mithralog EC-8042 inhibit SETDB1 expression and its oncogenic activity in malignant melanoma
Malignant melanoma is the most deadly skin cancer, associated with rising incidence and mortality rates. Most of the patients with melanoma, treated with current targeted therapies, develop a drug resistance, causing tumor relapse. The attainment of a better understanding of novel cancer-promoting m...
Saved in:
| Main Authors: | , , , , , , , |
|---|---|
| Format: | Article (Journal) |
| Language: | English |
| Published: |
September 2020
|
| In: |
Molecular therapy. Oncolytics
Year: 2020, Volume: 18, Pages: 83-99 |
| ISSN: | 2372-7705 |
| DOI: | 10.1016/j.omto.2020.06.001 |
| Online Access: | Verlag, lizenzpflichtig, Volltext: https://doi.org/10.1016/j.omto.2020.06.001 Verlag, lizenzpflichtig, Volltext: https://www.sciencedirect.com/science/article/pii/S2372770520300802 
|
| Author Notes: | Aniello Federico, Tamara Steinfass, Lionel Larribère, Daniel Novak, Francisco Morís, Luz-Elena Núñez, Viktor Umansky, and Jochen Utikal |
MARC
| LEADER | 00000naa a2200000 c 4500 | ||
|---|---|---|---|
| 001 | 1934757470 | ||
| 003 | DE-627 | ||
| 005 | 20250826152243.0 | ||
| 007 | cr uuu---uuuuu | ||
| 008 | 250826s2020 xx |||||o 00| ||eng c | ||
| 024 | 7 | |a 10.1016/j.omto.2020.06.001 |2 doi | |
| 035 | |a (DE-627)1934757470 | ||
| 035 | |a (DE-599)KXP1934757470 | ||
| 040 | |a DE-627 |b ger |c DE-627 |e rda | ||
| 041 | |a eng | ||
| 084 | |a 33 |2 sdnb | ||
| 100 | 1 | |a Federico, Aniello |d 1990- |e VerfasserIn |0 (DE-588)1197267964 |0 (DE-627)1679058754 |4 aut | |
| 245 | 1 | 0 | |a Mithramycin A and Mithralog EC-8042 inhibit SETDB1 expression and its oncogenic activity in malignant melanoma |c Aniello Federico, Tamara Steinfass, Lionel Larribère, Daniel Novak, Francisco Morís, Luz-Elena Núñez, Viktor Umansky, and Jochen Utikal |
| 246 | 3 | 3 | |a Mithramycin A and Mithralog EC-8042 inhibit SETDB one expression and its oncogenic activity in malignant melanoma |
| 264 | 1 | |c September 2020 | |
| 300 | |b Illustrationen | ||
| 300 | |a 17 | ||
| 336 | |a Text |b txt |2 rdacontent | ||
| 337 | |a Computermedien |b c |2 rdamedia | ||
| 338 | |a Online-Ressource |b cr |2 rdacarrier | ||
| 500 | |a Gesehen am 26.08.2025 | ||
| 520 | |a Malignant melanoma is the most deadly skin cancer, associated with rising incidence and mortality rates. Most of the patients with melanoma, treated with current targeted therapies, develop a drug resistance, causing tumor relapse. The attainment of a better understanding of novel cancer-promoting molecular mechanisms driving melanoma progression is essential for the development of more effective targeted therapeutic approaches. Recent studies, including the research previously conducted in our laboratory, reported that the histone methyltransferase SETDB1 contributes to melanoma pathogenesis. In this follow-up study, we further elucidated the role of SETDB1 in melanoma, showing that SETDB1 modulated relevant transcriptomic effects in melanoma, in particular, as activator of cancer-related secreted (CRS) factors and as repressor of melanocyte-lineage differentiation (MLD) and metabolic enzymes. Next, we investigated the effects of SETDB1 inhibition via compounds belonging to the mithramycin family, mithramycin A and mithramycin analog (mithralog) EC-8042: melanoma cells showed strong sensitivity to these drugs, which effectively suppressed the expression of SETDB1 and induced changes at the transcriptomic, morphological, and functional level. Moreover, SETDB1 inhibitors enhanced the efficacy of mitogen-activated protein kinase (MAPK) inhibitor-based therapies against melanoma. Taken together, this work highlights the key regulatory role of SETDB1 in melanoma and supports the development of SETDB1-targeting therapeutic strategies for the treatment of melanoma patients. | ||
| 700 | 1 | |a Steinfass, Tamara |d 1992- |e VerfasserIn |0 (DE-588)1272471241 |0 (DE-627)182159634X |4 aut | |
| 700 | 1 | |a Larribere, Lionel |e VerfasserIn |0 (DE-588)1118655079 |0 (DE-627)872164837 |0 (DE-576)479578648 |4 aut | |
| 700 | 1 | |a Novak, Daniel |d 1978- |e VerfasserIn |0 (DE-588)1026462975 |0 (DE-627)726763764 |0 (DE-576)371815533 |4 aut | |
| 700 | 1 | |a Morís, Francisco |e VerfasserIn |4 aut | |
| 700 | 1 | |a Núñez, Luz-Elena |e VerfasserIn |4 aut | |
| 700 | 1 | |a Umansky, Viktor |d 1955- |e VerfasserIn |0 (DE-588)102885756X |0 (DE-627)731733207 |0 (DE-576)376300078 |4 aut | |
| 700 | 1 | |a Utikal, Jochen |d 1974- |e VerfasserIn |0 (DE-588)1026463750 |0 (DE-627)726765015 |0 (DE-576)371816580 |4 aut | |
| 773 | 0 | 8 | |i Enthalten in |t Molecular therapy. Oncolytics |d Cambridge, MA : Cell Press, 2014 |g 18(2020) vom: Sept., Seite 83-99 |h Online-Ressource |w (DE-627)843857420 |w (DE-600)2842549-2 |w (DE-576)453321577 |x 2372-7705 |7 nnas |a Mithramycin A and Mithralog EC-8042 inhibit SETDB1 expression and its oncogenic activity in malignant melanoma |
| 773 | 1 | 8 | |g volume:18 |g year:2020 |g month:09 |g pages:83-99 |g extent:17 |a Mithramycin A and Mithralog EC-8042 inhibit SETDB1 expression and its oncogenic activity in malignant melanoma |
| 856 | 4 | 0 | |u https://doi.org/10.1016/j.omto.2020.06.001 |x Verlag |x Resolving-System |z lizenzpflichtig |3 Volltext |
| 856 | 4 | 0 | |u https://www.sciencedirect.com/science/article/pii/S2372770520300802 |x Verlag |z lizenzpflichtig |3 Volltext |
| 951 | |a AR | ||
| 992 | |a 20250826 | ||
| 993 | |a Article | ||
| 994 | |a 2020 | ||
| 998 | |g 1026463750 |a Utikal, Jochen |m 1026463750:Utikal, Jochen |d 60000 |e 60000PU1026463750 |k 0/60000/ |p 8 |y j | ||
| 998 | |g 102885756X |a Umansky, Viktor |m 102885756X:Umansky, Viktor |d 140000 |d 60000 |d 61900 |e 140000PU102885756X |e 60000PU102885756X |e 61900PU102885756X |k 0/140000/ |k 0/60000/ |k 1/60000/61900/ |p 7 | ||
| 998 | |g 1026462975 |a Novak, Daniel |m 1026462975:Novak, Daniel |d 60000 |d 61900 |e 60000PN1026462975 |e 61900PN1026462975 |k 0/60000/ |k 1/60000/61900/ |p 4 | ||
| 998 | |g 1118655079 |a Larribere, Lionel |m 1118655079:Larribere, Lionel |d 60000 |d 61900 |e 60000PL1118655079 |e 61900PL1118655079 |k 0/60000/ |k 1/60000/61900/ |p 3 | ||
| 998 | |g 1272471241 |a Steinfass, Tamara |m 1272471241:Steinfass, Tamara |d 140000 |d 60000 |d 61900 |e 140000PS1272471241 |e 60000PS1272471241 |e 61900PS1272471241 |k 0/140000/ |k 0/60000/ |k 1/60000/61900/ |p 2 | ||
| 999 | |a KXP-PPN1934757470 |e 4764328585 | ||
| BIB | |a Y | ||
| SER | |a journal | ||
| JSO | |a {"recId":"1934757470","titleAlt":[{"title":"Mithramycin A and Mithralog EC-8042 inhibit SETDB one expression and its oncogenic activity in malignant melanoma"}],"person":[{"display":"Federico, Aniello","role":"aut","given":"Aniello","roleDisplay":"VerfasserIn","family":"Federico"},{"family":"Steinfass","roleDisplay":"VerfasserIn","display":"Steinfass, Tamara","role":"aut","given":"Tamara"},{"family":"Larribere","roleDisplay":"VerfasserIn","given":"Lionel","display":"Larribere, Lionel","role":"aut"},{"given":"Daniel","display":"Novak, Daniel","role":"aut","family":"Novak","roleDisplay":"VerfasserIn"},{"given":"Francisco","display":"Morís, Francisco","role":"aut","family":"Morís","roleDisplay":"VerfasserIn"},{"display":"Núñez, Luz-Elena","role":"aut","given":"Luz-Elena","family":"Núñez","roleDisplay":"VerfasserIn"},{"given":"Viktor","display":"Umansky, Viktor","role":"aut","roleDisplay":"VerfasserIn","family":"Umansky"},{"display":"Utikal, Jochen","role":"aut","given":"Jochen","roleDisplay":"VerfasserIn","family":"Utikal"}],"relHost":[{"name":{"displayForm":["American Society of Gene & Cell Therapy"]},"physDesc":[{"extent":"Online-Ressource"}],"part":{"text":"18(2020) vom: Sept., Seite 83-99","volume":"18","year":"2020","extent":"17","pages":"83-99"},"type":{"bibl":"periodical","media":"Online-Ressource"},"origin":[{"dateIssuedDisp":"2017-","dateIssuedKey":"2017","publisherPlace":"Cambridge, MA ; London","publisher":"Cell Press ; Nature Publishing Group"}],"language":["eng"],"id":{"issn":["2372-7705"],"eki":["843857420"],"zdb":["2842549-2"]},"title":[{"partname":"Oncolytics","title":"Molecular therapy","title_sort":"Molecular therapy"}],"disp":"Mithramycin A and Mithralog EC-8042 inhibit SETDB1 expression and its oncogenic activity in malignant melanomaMolecular therapy. Oncolytics","note":["Gesehen am 19.09.2024"],"pubHistory":["Volume 1 (2014)-volume 31 (2023)"],"corporate":[{"roleDisplay":"Herausgebendes Organ","display":"American Society of Gene & Cell Therapy","role":"isb"}],"recId":"843857420"}],"title":[{"title":"Mithramycin A and Mithralog EC-8042 inhibit SETDB1 expression and its oncogenic activity in malignant melanoma","title_sort":"Mithramycin A and Mithralog EC-8042 inhibit SETDB1 expression and its oncogenic activity in malignant melanoma"}],"id":{"doi":["10.1016/j.omto.2020.06.001"],"eki":["1934757470"]},"note":["Gesehen am 26.08.2025"],"language":["eng"],"type":{"bibl":"article-journal","media":"Online-Ressource"},"origin":[{"dateIssuedDisp":"September 2020","dateIssuedKey":"2020"}],"name":{"displayForm":["Aniello Federico, Tamara Steinfass, Lionel Larribère, Daniel Novak, Francisco Morís, Luz-Elena Núñez, Viktor Umansky, and Jochen Utikal"]},"physDesc":[{"extent":"17 S.","noteIll":"Illustrationen"}]} | ||
| SRT | |a FEDERICOANMITHRAMYCI2020 | ||